# Biogen

pioneering complex biologic therapeutics targeting neurodegenerative diseases like Alzheimer's.

Source: https://en.bioecon.ru/companies/biogen/
Updated: 2026-06-24

- Country: United States
- Ticker: BIIB

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Headquarters | Cambridge, Massachusetts, United States | https://umbrex.com/resources/company-profiles/biogen/ |
| Production site | Research Triangle Park (Wake and Durham counties), North Carolina, United States | https://investors.biogen.com/node/29396/pdf, https://www.biogen.com/company/biogen-us-legacy.html, https://www.biogen.com/science-and-innovation/manufacturing.html |
| Production site | Solothurn, Switzerland | https://investors.biogen.com/news-releases/news-release-details/swissmedic-grants-good-manufacturing-practice-multi-product, https://www.biogen.com/science-and-innovation/manufacturing.html, https://www.bioprocessintl.com/regulations/biogen-swiss-site-gmp-ready-for-aducanumab-launch |
| Capacity | 263,000 liters of installed bioreactor capacity | https://www.biogen.com/science-and-innovation/manufacturing.html |
| Certification | Good Manufacturing Practice (GMP) multi-product license for Solothurn facility | https://investors.biogen.com/news-releases/news-release-details/swissmedic-grants-good-manufacturing-practice-multi-product, https://www.bioprocessintl.com/regulations/biogen-swiss-site-gmp-ready-for-aducanumab-launch |
| Funding | $200 million received in 2025 from Royalty Pharma with up to $50 million in 2026 for litifilimab development funding | https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm, https://www.sec.gov/Archives/edgar/data/875045/000119312526187407/d173896dars.pdf |

Independent sources: bioprocessintl.com, sec.gov, umbrex.com

## Technologies

- [Biopharmaceuticals & biomedicines](https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/)